Catalog No.
DHH02201
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q15116
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
REGN-2810, SAR-439684, cemiplimab-rwlc, CAS: 1801342-60-8
Clone ID
Cemiplimab
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma, PMID: 29863979
Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma, PMID: 32306208
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial, PMID: 31952975
Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma, PMID: 31524530
Cemiplimab, PMID: 31643611
Cemiplimab, PMID: 30372008
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing, PMID: 32554615
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies, PMID: 31796520
Cemiplimab: First Global Approval, PMID: 30456447
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer, PMID: 32917410
CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma, PMID: 31951149
Cemiplimab Approved for Treatment of CSCC, PMID: 30377167
Checkpoint Inhibitor-Induced Colitis, PMID: 31922959
Cemiplimab effective in cutaneous SCC, PMID: 29921845
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma, PMID: 33052055
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence, PMID: 32245016
Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma, PMID: 33068047
Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma, PMID: 31461085
Antibodies to watch in 2019, PMID: 30516432
Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies, PMID: 33146741
Immune checkpoint inhibitors to treat cutaneous malignancies, PMID: 32461079
RF-Cemiplimab: First Drug Approved for the Treatment of Metastatic or Unresectable Cutaneous Squamous Cell Carcinoma, PMID: 31874704
Correction to: Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma, PMID: 32474894
Update of the Management of Cutaneous Squamous-cell Carcinoma, PMID: 32346744
Epidermolysis bullosa: Advances in research and treatment, PMID: 31140655
Simultaneous response of cutaneous and lung squamous cell carcinoma with cemiplimab, PMID: 32614130
Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab, PMID: 33140115
[Cutaneous squamous cell carcinoma], PMID: 32583034
Posterior Uveitis Associated with Cemiplimab, PMID: 33793370
Actinic Keratosis and Cutaneous Squamous Cell Carcinoma, PMID: 32048593
The Landmark Series: Non-melanoma Skin Cancers, PMID: 31549317
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial, PMID: 33581821
Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma, PMID: 32149176
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology, PMID: 30917623
Cutaneous squamous cell carcinoma presenting with facial paralysis: good response to Cemiplimab, PMID: 32930485
Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma, PMID: 32905333
Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies, PMID: 33728546
Cemiplimab is a new option in BCC, PMID: 34035503
A Case of Miller Fisher Syndrome Due to the Use of Cemiplimab, PMID: 32868575
Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy, PMID: 31939072
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial, PMID: 34000246
Cemiplimab removed from reimbursable drugs in France, PMID: 33812142
Cemiplimab: a new option for the treatment of non-small-cell lung cancer, PMID: 34047193
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment, PMID: 32113942
Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text], PMID: 32746624
Medical treatment of advanced cutaneous squamous-cell carcinoma, PMID: 31833610
Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis, PMID: 33768419
Successful treatment of recurrent advanced cutaneous squamous cell carcinoma with cemiplimab, PMID: 33147669
Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes, PMID: 32815757
Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer, PMID: 34267641
For research use only. Not for human or drug use.
